Skye Bioscience to acquire UK's Redx Pharma in all-stock deal

What happened

Skye Bioscience, Inc., a San Diego-based pharmaceutical company, announced on August 14, 2026, that it has entered into a transaction agreement to acquire Redx Pharma Limited, a UK-based private company. The acquisition will be structured as a scheme of arrangement under UK law, in which Skye will issue shares of its common stock (and possibly non-voting common stock) to Redx shareholders in exchange for their Redx shares.

The deal implies a valuation of about $125 million for Redx and $14.5 million for Skye (subject to adjustments). Pro forma ownership after closing is expected to be: Redx shareholders about 46.17%, Skye's current shareholders about 5.38%, and new investors in a concurrent financing about 48.45%.

Skye's stock fell 4.81% on the announcement day to close at $0.515 per share, on volume about 6.7 times its average, according to price data.

The transaction details

The deal requires approval from both Skye's and Redx's shareholders, plus sanction by the High Court of England and Wales. Skye will file a proxy statement and hold a special meeting of its stockholders to vote on the share issuance and the resulting change of control.

Redx also plans to raise $36.0 million through a Series A financing before closing, and an existing Skye investor has agreed to invest up to $5 million more, with the overall concurrent financing targeted at $67.9 million.

After closing, Redx's management team will lead the combined company: Lisa Anson as CEO, Peter Collum as CFO, and other Redx executives in key roles. Current Skye executives and board members are expected to resign, and Redx will designate the new board of directors.

Skye will also issue contingent value rights (CVRs) to certain legacy stockholders, and the deal includes termination fees, lock-up agreements, and conditions including Nasdaq listing of the new shares.

What this means

A Form 8-K is a current report that public companies file with the SEC to announce major events, such as a material agreement or a change of control. This filing was made on August 14, 2026, covering items like the entry into the transaction agreement and the planned change in control.

A scheme of arrangement is a UK court-approved process for acquiring a company, similar to a merger but governed by UK law. It requires approval from the target's shareholders and court sanction.

The exchange ratio determines how many Skye shares each Redx shareholder receives. The low pro forma ownership for Skye's current shareholders (5.38%) reflects the company's small valuation relative to Redx and the planned financing.

CVRs are contractual rights that pay out based on future events, such as achieving certain milestones. Here, they are being given to certain Skye legacy stockholders as part of the deal.

The deal still faces shareholder votes and court approval. If all conditions are met, the transaction could close after October 31, 2026, unless the 'Specified Adjustment' is resolved earlier. The stock decline suggests investors may be reacting to dilution or the change of control, but the filing does not explain the price move.